These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia. Berkhof J, Bogaards JA, Demirel E, Diaz M, Sharma M, Kim JJ. Vaccine; 2013 Dec 31; 31 Suppl 7():H71-9. PubMed ID: 24332299 [Abstract] [Full Text] [Related]
7. Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA). Kim JJ, Sharma M, O'Shea M, Sweet S, Diaz M, Sancho-Garnier H, Seoud M. Vaccine; 2013 Dec 30; 31 Suppl 6():G65-77. PubMed ID: 24331822 [Abstract] [Full Text] [Related]
8. Recommendations for cervical cancer prevention in Asia Pacific. Garland SM, Cuzick J, Domingo EJ, Goldie SJ, Kim YT, Konno R, Parkin DM, Qiao YL, Sankaranarayanan R, Stern PL, Tay SK, Bosch FX. Vaccine; 2008 Aug 19; 26 Suppl 12():M89-98. PubMed ID: 18945418 [Abstract] [Full Text] [Related]
11. HPV testing and vaccination in Europe. Leeson SC, Alibegashvili T, Arbyn M, Bergeron C, Carriero C, Mergui JL, Nieminen P, Prendiville W, Redman CW, Rieck GC, Quaas J, Petry KU. J Low Genit Tract Dis; 2014 Jan 19; 18(1):61-9. PubMed ID: 23774078 [Abstract] [Full Text] [Related]
12. HPV Vaccination and Cervical Cancer Screening Policies and Practices in 18 Countries, Territories and Entities across Eastern Europe and Central Asia. Davies P, Aluloski I, Arifdjanova D, Brcanski J, Davidzenka A, Durdyeva A, Gayrat Umarzoda S, Goshliyev K, Jovanovic V, Jugeli L, Kocinaj-Berisha M, Maistruk G, Naumovic T, Pilav A, Rzayeva G, Saribekyan K, Siljak S, Ten E, Valuta D, Veljkovic M, Yildirimkaya G, Ylli A, Zhylkaidarova A, Melnic E. Asian Pac J Cancer Prev; 2023 May 01; 24(5):1781-1788. PubMed ID: 37247301 [Abstract] [Full Text] [Related]
17. Prevalence of type-specific human papillomavirus infection among women in France: Implications for screening, vaccination, and a future generation of multivalent HPV vaccines. Monsonego J, Zerat L, Syrjänen K, Zerat JC, Smith JS, Halfon P. Vaccine; 2012 Jul 27; 30(35):5215-21. PubMed ID: 22713720 [Abstract] [Full Text] [Related]
20. Pre-vaccination prevalence of infections with 25 non-high-risk human papillomavirus types among 1,000 Slovenian women in cervical cancer screening. Učakar V, Poljak M, Oštrbenk A, Klavs I. J Med Virol; 2014 Oct 27; 86(10):1772-9. PubMed ID: 24978445 [Abstract] [Full Text] [Related] Page: [Next] [New Search]